Legal Experts Dive Into Allarity Therapeutics, Inc.’s Compliance
Legal experts are delving into the compliance of Allarity Therapeutics, Inc. (referred to as “Allarity” or the “Company”) amid concerns surrounding potential violations of federal securities laws.
Shareholders who have suffered losses are invited to participate in the investigation, as Allarity disclosed an alarming development on July 22, 2024. The Company received a Wells Notice from the U.S. Securities and Exchange Commission related to its statements concerning meetings with the U.S. Food and Drug Administration regarding its NDA for the drug, Dovitnib, which was submitted in 2021. Additionally, three former officers of Allarity have also received Wells Notices. These notices signal a preliminary determination by the SEC Staff to recommend an enforcement action alleging violations of federal securities laws against the Company.
For the latest updates, interested parties can follow the developments on Twitter via a dedicated channel.
Shareholders who have invested in Allarity securities or possess relevant information about these claims are encouraged to reach out for further clarification. Contact details for Frank R. Cruz, of The Law Offices of Frank R. Cruz, are provided as follows: 2121 Avenue of the Stars, Suite 800, Century City, California 90067; phone: 310-914-5007; email: info@frankcruzlaw.com; website: www.frankcruzlaw.com. When reaching out via email, make sure to include your mailing address, telephone number, and the number of shares purchased.
Disclaimer: This press release may be considered Attorney Advertising in specific jurisdictions under relevant legal and ethical guidelines.
